| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | S Ananth Karumanchi | Q69022759 |
| P2093 | author name string | Walter P Mutter | |
| P2860 | cites work | Excessive placental secretion of neurokinin B during the third trimester causes pre-eclampsia | Q22254337 |
| Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1 | Q24316075 | ||
| Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor | Q24320710 | ||
| Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells | Q24337230 | ||
| Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion? | Q24561702 | ||
| Angiopoietin-1 and angiopoietin-2 activate trophoblast Tie-2 to promote growth and migration during placental development | Q24669641 | ||
| Circulating levels of immunoreactive cytokines in women with preeclampsia | Q77384781 | ||
| VASCULAR REACTIVITY TO ANGIOTENSIN II AND NOREPINEPHRINE IN PREGNANT WOMEN | Q78231835 | ||
| Impaired oxygen-dependent reduction of HIF-1alpha and -2alpha proteins in pre-eclamptic placentae | Q78881775 | ||
| Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia | Q80496353 | ||
| Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop | Q80914460 | ||
| The fetal vascularisation of term human placental villi. I. Peripheral stem villi | Q93656368 | ||
| Expression of inflammatory cytokines in placentas from women with preeclampsia | Q73992120 | ||
| Oxidative stress and altered endothelial cell function in preeclampsia | Q74757937 | ||
| Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients | Q74788028 | ||
| Obesity and preeclampsia: the potential role of inflammation | Q77156957 | ||
| Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts | Q28186129 | ||
| Pre-eclampsia and thrombophilia | Q28196374 | ||
| What we have learned about preeclampsia | Q28196892 | ||
| Human placental vascular development: vasculogenic and angiogenic (branching and nonbranching) transformation is regulated by vascular endothelial growth factor-A, angiopoietin-1, and angiopoietin-2 | Q28221171 | ||
| Soluble endoglin contributes to the pathogenesis of preeclampsia | Q28244053 | ||
| Mapping the theories of preeclampsia and the role of angiogenic factors: a systematic review | Q28281326 | ||
| Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia | Q29615916 | ||
| Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis | Q29617644 | ||
| Severe maternal morbidity associated with hypertensive disorders in pregnancy in the United States | Q33349406 | ||
| Implantation and the placenta: key pieces of the development puzzle | Q33367178 | ||
| High body mass index and hypercholesterolemia: risk of hypertensive disorders of pregnancy | Q33746742 | ||
| Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor | Q33848380 | ||
| Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) and soluble Flt-1 by oxygen--a review. | Q33930029 | ||
| Pathogenesis and genetics of pre-eclampsia | Q33934445 | ||
| Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study | Q33947553 | ||
| Pre-eclampsia | Q34079933 | ||
| Hypoxia induces endothelin gene expression and secretion in cultured human endothelium | Q34200622 | ||
| A study of angiotensin II pressor response throughout primigravid pregnancy | Q34512573 | ||
| Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer | Q34530109 | ||
| Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases | Q34835409 | ||
| Vascular endothelial growth factor localization in the adult. | Q35087955 | ||
| The human placenta remodels the uterus by using a combination of molecules that govern vasculogenesis or leukocyte extravasation | Q35157745 | ||
| Glomerular endothelial cell differentiation. | Q36102370 | ||
| A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer | Q36509678 | ||
| Pre-eclampsia in pregnancy and subsequent risk for breast cancer | Q36624347 | ||
| Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? | Q37366512 | ||
| Cancer after pre-eclampsia: follow up of the Jerusalem perinatal study cohort | Q37515561 | ||
| Oxygen and placental development during the first trimester: implications for the pathophysiology of pre-eclampsia | Q38311843 | ||
| Control of vascular reactivity in pregnancy | Q39766605 | ||
| Endothelial dysfunction: a link among preeclampsia, recurrent pregnancy loss, and future cardiovascular events? | Q40268212 | ||
| Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia | Q40530224 | ||
| Prostacyclin and thromboxane changes predating clinical onset of preeclampsia: a multicenter prospective study | Q40802999 | ||
| Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. | Q41091104 | ||
| High plasma cellular fibronectin levels correlate with biochemical and clinical features of preeclampsia but cannot be attributed to hypertension alone | Q41171718 | ||
| Preeclampsia: an endothelial cell disorder | Q41281924 | ||
| Colocalisation of vascular endothelial growth factor and its Flt-1 receptor in human placenta | Q41385756 | ||
| Fetal vasculogenesis and angiogenesis in human placental villi. | Q42490918 | ||
| Association of maternal endothelial dysfunction with preeclampsia | Q43553727 | ||
| Pregnancy, preeclampsia, and the endothelial cell | Q43778881 | ||
| Placental characteristics and reduced risk of maternal breast cancer | Q44069259 | ||
| Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia | Q44434565 | ||
| Adverse pregnancy outcomes in snuff users | Q44982635 | ||
| A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia | Q45271925 | ||
| Human cytotrophoblasts promote endothelial survival and vascular remodeling through secretion of Ang2, PlGF, and VEGF-C | Q46130400 | ||
| Trophoblast pseudo-vasculogenesis: faking it with endothelial adhesion receptors | Q46258674 | ||
| Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. | Q46339760 | ||
| Preeclampsia and subsequent risk of cancer in Utah | Q46341131 | ||
| Regulation of human placental development by oxygen tension | Q46733260 | ||
| Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness | Q46841539 | ||
| Circulating angiogenic factors and the risk of preeclampsia | Q47217679 | ||
| Endothelial dysfunction in preeclampsia | Q47879591 | ||
| Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia | Q47915288 | ||
| Insulin resistance and alterations in angiogenesis: additive insults that may lead to preeclampsia | Q47945074 | ||
| Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity. | Q47974115 | ||
| Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award | Q48348609 | ||
| Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. | Q51037240 | ||
| Fasting serum triglycerides, free fatty acids, and malondialdehyde are increased in preeclampsia, are positively correlated, and decrease within 48 hours post partum. | Q51582611 | ||
| Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia. | Q52940276 | ||
| Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. | Q53600812 | ||
| The fetal vascularisation of term human placental villi. II. Intermediate and terminal villi. | Q53889480 | ||
| First trimester insulin resistance and subsequent preeclampsia: a prospective study. | Q53974694 | ||
| Glomerular endothelial cells are maintained by vascular endothelial growth factor in the adult kidney. | Q54695121 | ||
| Urinary Placental Growth Factor and Risk of Preeclampsia | Q56619498 | ||
| Elevated Serum Soluble Vascular Endothelial Growth Factor Receptor 1 (sVEGFR-1) Levels in Women with Preeclampsia | Q56619500 | ||
| Soluble fms-Like Tyrosine Kinase 1 Is Increased in Preeclampsia But Not in Normotensive Pregnancies with Small-for-Gestational-Age Neonates: Relationship to Circulating Placental Growth Factor | Q56619503 | ||
| Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1 | Q57105968 | ||
| Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study | Q57408925 | ||
| Neutralization of Circulating Vascular Endothelial Growth Factor (VEGF) by Anti-VEGF Antibodies and Soluble VEGF Receptor 1 (sFlt-1) Induces Proteinuria | Q58214894 | ||
| Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia | Q58778301 | ||
| Plasma of Preeclamptic Women Stimulates and Then Inhibits Endothelial Prostacyclin | Q59367817 | ||
| Plasma endothelin levels in preeclampsia: elevation and correlation with uric acid levels and renal impairment | Q68053902 | ||
| The role of the spiral arteries in the pathogenesis of preeclampsia | Q69446253 | ||
| Elevated circulating thrombomodulin in severe preeclampsia | Q70465980 | ||
| Uteroplacental blood flow in pregnancy induced hypertension | Q70962358 | ||
| [Measuring the concentration of various plasma and placenta extract proteolytic and vascular factors in pregnant patients with HELLP syndrome, pre-/eclampsia and highly pathologic Doppler flow values] | Q71166954 | ||
| Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR | Q71530460 | ||
| Proteases and their inhibitors are indicative in gestational disease | Q71716172 | ||
| Preeclampsia -- a state of sympathetic overactivity | Q71723202 | ||
| Abnormal endothelial cell function of resistance arteries from women with preeclampsia | Q72077460 | ||
| Biochemical corroboration of endothelial involvement in severe preeclampsia | Q72524938 | ||
| Nitric oxide-mediated vasodilation in human pregnancy | Q73281658 | ||
| Tie-2 and angiopoietin-2 expression at the fetal-maternal interface: a receptor ligand model for vascular remodelling | Q73302523 | ||
| Selective overexpression of the hypoxia-inducible transcription factor, HIF-2alpha, in placentas from women with preeclampsia | Q73399793 | ||
| Flow-mediated vasodilatation is enhanced in normal pregnancy but reduced in preeclampsia | Q73595868 | ||
| AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor | Q73815485 | ||
| P433 | issue | 1 | |
| P921 | main subject | maternal health | Q6786626 |
| pre-eclampsia | Q61335 | ||
| P304 | page(s) | 1-8 | |
| P577 | publication date | 2007-05-06 | |
| P1433 | published in | Microvascular Research | Q15752704 |
| P1476 | title | Molecular mechanisms of preeclampsia | |
| P478 | volume | 75 |
| Q37257615 | A recently evolved novel trophoblast-enriched secreted form of fms-like tyrosine kinase-1 variant is up-regulated in hypoxia and preeclampsia |
| Q33418645 | ADAMTS-13 in the Diagnosis and Management of Thrombotic Microangiopathies |
| Q46491999 | Abnormal Placentation Associated with Infertility as a Marker of Overall Health |
| Q33946049 | Abnormal oxidative stress responses in fibroblasts from preeclampsia infants |
| Q46277807 | Alterations of IL-6, IL-6R and gp130 in early and late onset severe preeclampsia |
| Q51785852 | Alterations of maternal serum and placental follistatin-like 3 and myostatin in pre-eclampsia. |
| Q38841519 | Altered folate metabolism modifies cell proliferation and progesterone secretion in human placental choriocarcinoma JEG-3 cells |
| Q28109684 | An Integrative Analysis of Preeclampsia Based on the Construction of an Extended Composite Network Featuring Protein-Protein Physical Interactions and Transcriptional Relationships |
| Q54613364 | Angiogenic factors in maternal circulation and the risk of severe fetal growth restriction. |
| Q43939628 | Angiotensin type 1 receptor autoantibody from preeclamptic patients induces human fetoplacental vasoconstriction |
| Q93088427 | Assessment of the SFlt-1 and sFlt-1/25(OH)D Ratio as a Diagnostic Tool in Gestational Hypertension (GH), Preeclampsia (PE), and Gestational Diabetes Mellitus (GDM) |
| Q34705582 | Association between Angiotensinogen M235T Polymorphism and Preeclampsia in Iranian Pregnant Women. |
| Q28749412 | Association between local traffic-generated air pollution and preeclampsia and preterm delivery in the south coast air basin of California |
| Q37153701 | Association of Gestational Hypertensive Disorders with Retinopathy of prematurity: A Systematic Review and Meta-analysis |
| Q33762529 | Autonomic circulatory control during pregnancy in humans |
| Q37156676 | Biomarkers for the management of pre-eclampsia in pregnant women. |
| Q38542456 | Cardiac Physiology of Pregnancy |
| Q36428404 | Cardiovascular mortality after pre-eclampsia in one child mothers: prospective, population based cohort study |
| Q28081588 | Circadian System and Melatonin Hormone: Risk Factors for Complications during Pregnancy |
| Q34670638 | Circulating angiogenic and antiangiogenic factors in women with eclampsia |
| Q26801503 | Combined Screening for Early Detection of Pre-Eclampsia |
| Q35567911 | Diagnostic accuracy of the soluble Fms-like tyrosine kinase-1/placental growth factor ratio for preeclampsia: a meta-analysis based on 20 studies |
| Q37157819 | Diagnostic and prognostic significance of serum soluble endoglin levels in preeclampsia and eclampsia |
| Q36120785 | Difference of concentration of placental soluble fms-like tyrosine kinase-1(sFlt-1), placental growth factor (PlGF), and sFlt-1/PlGF ratio in severe preeclampsia and normal pregnancy |
| Q33801203 | Dysregulation of promyelocytic leukemia (PML) protein expression in preeclamptic placentae. |
| Q36407107 | Elevated Soluble Fms-Like Tyrosine Kinase-1 and Placental-Like Growth Factor Levels Are Associated With Development and Mortality Risk in Heart Failure |
| Q33813477 | Endothelin-dependent vasoconstriction in human uterine artery: application to preeclampsia |
| Q35824650 | Epigenetics and Preeclampsia: Defining Functional Epimutations in the Preeclamptic Placenta Related to the TGF-β Pathway |
| Q53203097 | Evaluation of 5-HT7 receptor expression in the placentae of normal and pre-eclamptic women. |
| Q92980466 | Evaluation of Serum Biomarkers and Other Diagnostic Modalities for Early Diagnosis of Preeclampsia |
| Q35930887 | Expression Profile of MicroRNAs and mRNAs in Human Placentas From Pregnancies Complicated by Preeclampsia and Preterm Labor |
| Q36317661 | Expression and significance of miR155 and vascular endothelial growth factor in placenta of rats with preeclampsia |
| Q37703260 | Fetal growth restriction - from observation to intervention |
| Q37474300 | Fetal origins of autism spectrum disorders: the non-associated maternal factors |
| Q34984367 | Folic acid supplementation attenuates hyperhomocysteinemia-induced preeclampsia-like symptoms in rats |
| Q82038267 | Haptoglobin phenotype in women with preeclampsia |
| Q54360704 | How placental growth factor detection might improve diagnosis and management of pre-eclampsia. |
| Q38400715 | Hypertension in pregnancy: natural history and treatment options |
| Q40885494 | Hypertensive disorders of pregnancy and subsequent risk of solid cancer--A nationwide cohort study. |
| Q37173281 | Identification of ligand-induced proteolytic cleavage and ectodomain shedding of VEGFR-1/FLT1 in leukemic cancer cells |
| Q37850374 | Inflammatory pattern recognition receptors and their ligands: factors contributing to the pathogenesis of preeclampsia |
| Q34436853 | Lipid peroxidation is not associated with adipocytokines in preeclamptic women |
| Q35060531 | LncRNAs expression in preeclampsia placenta reveals the potential role of LncRNAs contributing to preeclampsia pathogenesis |
| Q92647905 | Long-term cardiovascular disorders in the STOX1 mouse model of preeclampsia |
| Q37748773 | Markers of preeclampsia and the relationship to cardiovascular disease: review of the twenty-first century literature |
| Q35827036 | Maternal angiogenic profile in pregnancies that remain normotensive |
| Q34797328 | Maternal peripheral blood gene expression in early pregnancy and preeclampsia. |
| Q36910638 | Matrix metalloproteinases as drug targets in preeclampsia |
| Q38120774 | MicroRNA analysis in placentas from patients with preeclampsia: comparison of new and published results |
| Q47643595 | MoM cutoffs for variables, an important tool for multivariate analysis and accurate interpretation of preeclampsia risk in high-risk pregnancy at 11-13+6 weeks gestation |
| Q55689625 | Mutual Balance between Vasohibin-1 and Soluble VEGFR-1 in Endothelial Cells. |
| Q34075184 | Myocardial late gadolinium enhancement cardiovascular magnetic resonance in patients with cirrhosis. |
| Q90751181 | Nitric oxide and the biology of pregnancy |
| Q35721088 | Nitric oxide generation affects pro- and anti-angiogenic growth factor expression in primary human trophoblast |
| Q26746049 | No Hypertensive Disorder of Pregnancy; No Preeclampsia-eclampsia; No Gestational Hypertension; No Hellp Syndrome. Vascular Disorder of Pregnancy Speaks for All |
| Q40561932 | Novel "omics" approach for study of low-abundance, low-molecular-weight components of a complex biological tissue: regional differences between chorionic and basal plates of the human placenta |
| Q37465594 | Novel approaches for mechanistic understanding and predicting preeclampsia |
| Q33738656 | Oxidative injury of the pulmonary circulation in the perinatal period: Short- and long-term consequences for the human cardiopulmonary system |
| Q50352405 | Oxidative stress and endothelial function in normal pregnancy versus pre-eclampsia, a combined longitudinal and case control study |
| Q34617481 | Oxygen-Dependent Gene Expression in Development and Cancer: Lessons Learned from the Wilms' Tumor Gene, WT1 |
| Q26865332 | Pathophysiology of hypertension in pre-eclampsia: a lesson in integrative physiology |
| Q33693037 | Pathophysiology of ischemic placental disease |
| Q30408297 | Peri-implantation hormonal milieu: elucidating mechanisms of abnormal placentation and fetal growth |
| Q38089817 | Physiological and pathophysiological roles of placental aminopeptidase in maternal sera: possible relation to preeclampsia and preterm delivery |
| Q38272641 | Placenta-derived angiogenic proteins and their contribution to the pathogenesis of preeclampsia |
| Q37483999 | Placental ischemia and breast cancer risk after preeclampsia: tying the knot |
| Q35860239 | Pre-eclampsia and offspring cardiovascular health: mechanistic insights from experimental studies |
| Q37991228 | Pre-eclampsia following chemotherapy for breast cancer during pregnancy: case report and review of the literature |
| Q46302568 | Pre-eclampsia: Molecular events to biomarkers |
| Q35853166 | Prediction of Fetal Growth Restriction by Analyzing the Messenger RNAs of Angiogenic Factor in the Plasma of Pregnant Women |
| Q35051099 | Preeclampsia and diabetes |
| Q35798781 | Preeclampsia in pregnancy and later use of antihypertensive drugs |
| Q27000388 | Preeclampsia, hypoxia, thrombosis, and inflammation |
| Q35153313 | Pregnancy after kidney transplantation |
| Q37392711 | Pregnancy characteristics and maternal breast cancer risk: a review of the epidemiologic literature |
| Q34255236 | Pregnancy-induced hypertension and preeclampsia: levels of angiogenic factors in malaysian women |
| Q35671379 | Proteases and sFlt-1 release in the human placenta |
| Q28080015 | Putative Key Role of Inositol Messengers in Endothelial Cells in Preeclampsia |
| Q43568059 | Quitting smoking during early versus late pregnancy: the risk of preeclampsia and adverse birth outcomes |
| Q34404445 | Recent insights into the pathophysiology of preeclampsia |
| Q35683468 | Recombinant vascular endothelial growth factor 121 attenuates autoantibody-induced features of pre-eclampsia in pregnant mice |
| Q52319477 | Relationship between human leukocyte antigen (HLA)-DQA1*0102/HLA-DQB1*0602 polymorphism and preeclampsia. |
| Q33793455 | Risk factors and mediators of the vascular dysfunction associated with hypertension in pregnancy |
| Q33783531 | Role of biomarkers in early detection of preeclampsia |
| Q46823568 | Serial multimodal monitoring of cerebral manifestations in eclampsia and comparison with normal pregnancy: a clinical study |
| Q37377138 | Serum 25(OH) Vitamin D Levels in Polish Women during Pregnancies Complicated by Hypertensive Disorders and Gestational Diabetes. |
| Q41475835 | Serum magnesium and calcium in preeclampsia: A comparative study at the Korle-Bu Teaching Hospital, Ghana |
| Q35071433 | Severe early-onset preeclampsia is not associated with a change in placental catechol O-methyltransferase (COMT) expression. |
| Q50485046 | Spatial Memory in the Progeny of Rats Subjected to Different Types of Experimental Preeclampsia. |
| Q40438431 | Symptoms of Depression Predict Negative Birth Outcomes in African American Women: A Pilot Study |
| Q91892304 | Syncytiotrophoblast extracellular microvesicle profiles in maternal circulation for noninvasive diagnosis of preeclampsia |
| Q34056273 | Syncytiotrophoblast microvesicles released from pre-eclampsia placentae exhibit increased tissue factor activity |
| Q30438979 | Systems biology of vascular endothelial growth factors |
| Q35043430 | The association between hypertensive disorders in pregnancy and bronchopulmonary dysplasia: a systematic review |
| Q26798193 | The imbalance in expression of angiogenic and anti-angiogenic factors as candidate predictive biomarker in preeclampsia |
| Q33634903 | The maternal brain: an organ with peripartal plasticity |
| Q53443775 | The outcome of pregnancy with new onset proteinuria without hypertension: retrospective observational study. |
| Q37041658 | The role of angiogenic, anti-angiogenic and vasoactive factors in pre-eclamptic African women: early- versus late-onset pre-eclampsia |
| Q33668328 | The therapeutic potential of antioxidants, ER chaperones, NO and H2S donors, and statins for treatment of preeclampsia |
| Q35107355 | The ubiquitin ligase ASB4 promotes trophoblast differentiation through the degradation of ID2 |
| Q33389435 | Thrombotic microangiopathies: multimers, metalloprotease, and beyond |
| Q51332754 | Use of serum and urinary soluble sFlt-1 and PLGF in the diagnosis of preeclampsia. |
| Q38124456 | Vascular dysfunction in preeclampsia |
| Q54355512 | Vascular endothelial growth factor (VEGF) and the VEGF soluble receptor-1 (sFlt-1) in chorionic villus tissue from Chinese women with early recurrent spontaneous abortion. |
| Q37353319 | Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression |
| Q37616832 | Vascular pool of releasable soluble VEGF receptor-1 (sFLT1) in women with previous preeclampsia and uncomplicated pregnancy |
| Q34173305 | Vasopressin in preeclampsia: a novel very early human pregnancy biomarker and clinically relevant mouse model |
Search more.